Abstract Number: 0429 • ACR Convergence 2025
Real-world experience of upadacitinib therapy in difficult-to-treat juvenile idiopathic arthritis: a case series of 24 patients
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease. Some patients experiencing active disease due to inadequate responses to conventional treatments. Studies have demonstrated…Abstract Number: 0409 • ACR Convergence 2025
Discordance Between Disease Activity and Patient-Reported Outcomes in Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Outcome assessment is essential to optimize care for patients with juvenile idiopathic arthritis (JIA). Although disease activity and patient-reported outcomes (PROs) are different measures,…Abstract Number: 0387 • ACR Convergence 2025
Association Between Juvenile Arthritis and Physical Activity Levels in U.S. Children: A Cross-Sectional Study Using the 2016–2021 National Survey of Children’s Health
Background/Purpose: Juvenile arthritis (JA) is characterized by joint pain, stiffness, and decreased mobility, potentially affecting participation in physical activity (PA). Current guidelines from the CDC…Abstract Number: 2138 • ACR Convergence 2025
Factors driving therapeutic decision-making in Still’s Disease: When to Start and When to Stop? Data from the METAPHOR Project Worldwide Survey
Background/Purpose: Despite continuous improvement in care and the recent update of international recommendations, relevant discrepancies in the diagnostic and treatment approach to Still’s disease (SD)…Abstract Number: 1813 • ACR Convergence 2025
Frequency of Tissue-Specific Activated CD8+ T Cells is Correlated To Disease Severity in Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is characterized by joint pain and inflammation. Persistent oligoarticular JIA(oligoJIA) is defined by the involvement of up to 4 joints…Abstract Number: 0426 • ACR Convergence 2025
Tofacitinib in Juvenile Idiopathic Arthritis: efficacy and safety in a clinical practice setting.
Background/Purpose: This study aims to evaluate the efficacy and safety of tofacitnib, a JAK inhibitor, in a multicentric cohort of patients with juvenile idiopathic arthritis…Abstract Number: 0407 • ACR Convergence 2025
The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort
Background/Purpose: Childhood chronic non-infectious uveitis (cNIU) is a sight-threatening condition that can lead to blindness if not appropriately treated. cNIU is typically associated with Juvenile…Abstract Number: 0312 • ACR Convergence 2025
Efficacy and Safety of Tocilizumab in Children with Juvenile Idiopathic Arthritis: A Systematic Review and Meta-Analysis
Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses various chronic inflammatory conditions in children that lead to joint discomfort and potential disability. Tocilizumab, an antibody targeting interleukin-6,…Abstract Number: 2137 • ACR Convergence 2025
Therapeutic Strategies in Newly Diagnosed Still’s Disease: Real-Life Clinicians’ Choices from the METAPHOR Project Worldwide Survey
Background/Purpose: Despite continuous advances in care and the recent publication of updated international recommendations, relevant discrepancies in the management of Still’s disease (SD) may still…Abstract Number: 1812 • ACR Convergence 2025
Inflammasome and UPR activation in monocytes of HLA B27 positive children with Enthesitis related arthritis category of JIA
Background/Purpose: Enthesitis related arthritis (ERA) is a chronic immune-inflammatory disease with unknown etiology. HLA-B27 is the strongest risk factor predisposing to ERA like Spondyloarthritis (SpA).…Abstract Number: 0427 • ACR Convergence 2025
Maternal Smoking During Pregnancy and Risk of Juvenile Idiopathic Arthritis (JIA): Triangulating Evidence from Polygenic Risk Scores and Meta-Analysis in Scandinavian Birth Cohorts
Background/Purpose: Maternal smoking during pregnancy has been associated with a seemingly lower risk of juvenile idiopathic arthritis (JIA) in the child (1), contrasting with smoking’s…Abstract Number: 0406 • ACR Convergence 2025
Comparing biomarkers associated with uveitis in tear fluid and serum samples of children with Juvenile Idiopathic Arthritis
Background/Purpose: Chronic anterior uveitis (CAU) develops in 15-20% of juvenile idiopathic arthritis (JIA) cases. Early detection may prevent vision loss. However, known clinical risk factors…Abstract Number: 0028 • ACR Convergence 2025
Computational and Laboratory Identification of Risk-Driving Alleles on Juvenile Idiopathic Arthritis (JIA)-Associated Haplotypes
Background/Purpose: Multiple genomic regions are known to confer risk for JIA. However, identifying the SNPs that exert the biological effects that confer risk, and therefore…Abstract Number: 2134 • ACR Convergence 2025
Krebs von den Lungen-6 (KL-6) as a Potential Diagnostic Biomarker of Lung Disease in Pediatric Systemic Juvenile Idiopathic Arthritis: Preliminary Findings from a Multisite US Cohort
Background/Purpose: Children with Systemic Juvenile Idiopathic Arthritis (SJIA) who develop lung disease (LD) are at significantly increased risk of serious complications and even death. Early…Abstract Number: 1811 • ACR Convergence 2025
Pharmacogenomic analysis of prediction of IL-1 Inhibitor treatment response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study
Background/Purpose: Interleukin (IL)-1 inhibitors are now regarded as the first line treatment option for systemic juvenile idiopathic arthritis (sJIA), however in up to half of…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 25
- Next Page »